DAPA-HF trial
Also written as: DAPA-HF — Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Heart failure outcomes trial demonstrating benefits of dapagliflozin in patients with heart failure with reduced ejection fraction.
Full Definition
DAPA-HF (Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction) was a randomized controlled trial that enrolled nearly 5,000 patients with heart failure with reduced ejection fraction (HFrEF), both with and without diabetes. The trial demonstrated that dapagliflozin significantly reduced the composite endpoint of cardiovascular death or worsening heart failure compared to placebo, with benefits seen regardless of diabetes status. This landmark trial established SGLT2 inhibitors as a new pillar of heart failure therapy and led to regulatory approval of dapagliflozin for heart failure treatment.
Usage
Usage note: Established SGLT2 inhibitors as heart failure therapy independent of diabetes status.
In Context
- "DAPA-HF trial results led to updated heart failure guidelines recommending SGLT2 inhibitors for all eligible patients." — Clinical practice guideline
- "The cardiology team initiated dapagliflozin based on compelling DAPA-HF evidence for heart failure mortality reduction." — Clinical decision note